Trials / Terminated
TerminatedNCT03701438
Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib
Immune Response to Influenza Vaccine in Subjects With B-cell Malignancies Treated With Idelalisib
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 2 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the immune response to an influenza vaccine in adults with B-cell malignancies who are currently receiving treatment with idelalisib in a Gilead-sponsored study (parent study).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Influenza Vaccine | Administered per standard of care using a vaccine licensed and recommended in the site's country |
Timeline
- Start date
- 2018-10-23
- Primary completion
- 2019-10-09
- Completion
- 2019-10-09
- First posted
- 2018-10-10
- Last updated
- 2020-02-20
Locations
2 sites across 2 countries: Czechia, Spain
Source: ClinicalTrials.gov record NCT03701438. Inclusion in this directory is not an endorsement.